Shanghai Shengsheg Parceutical Sarkar Col Sarkar Co., Ltd. (na nan da ke da karfi sarkar sarkar sarkar sarkar sarkar sarkar sarkar sarkar sabis na kasar Sin. Tunda kafuwarsa, kamfanin ya yi mai da hankali kan samar da cikakken sarkar da aka hade da abokan sarkar a cikin binciken magunguna da ci gaba, kimiyyar rayuwa, da kuma kasuwanci ya gama magunguna. Tare da shekaru goma na ƙwarewar ƙwarewa da fasaha, Shanghai Shengsuneng ci gaba da kirkirar masana'antar da kuma ka'idojin aikin masana'antu.
A ranar 30 ga Yuni na wannan shekara, Shanghai Shengsuneng ya ƙaddamar da kayan jinginsa da karban karba, na nufin IPO a babban kwamitin musayar jari na Shanghai. A ranar 28 ga Yuli, ya karbi farkon binciken bincike, amma kamar yadda yanzu, kamfanin bai amsa ba. Tallafin jerin kamfanin na kamfani shine kamfanoni na ƙasa na ƙasa na kasar Sin (CICC).
A ranar 30 ga Satumba, 2023, saboda bayanan kuɗi da aka rubuta a cikin takardun aikace-aikacen don bayarwa da jerin abubuwan da suka ƙare, ana buƙatar ƙaddamar da aiki. A cewar Mataki na ashirin da 60 daga cikin Shanghai Stock Canjin hannun jari da kuma jerin dokokin sake dubawa, an dakatar da binciken Shanghai Shengsuneng da jerin abubuwan da aka dakatar.
Dangane da bayanan da suka cika sakamakon kudaden shiga, kudaden shiga Shanghai Shengsuneng a shekarar 2022 ya kasance Yuan miliyan 630 na Yuan. Kamfanin yana shirin tunan Yuan miliyan 900 na wannan lokacin, tare da kimar kasuwar kasashe kimanin Yuan biliyan 6 bayan jerin abubuwa.
Sabis ɗin Biopharmaceututical Col Sarkar Sarkar Sarkar da aka bayar don tsarin zafin jiki na biopharmautical na samfuran bipharmautical na samfuran sarrafawa da kuma shirye-shiryen sarrafa zazzabi da kuma shirye-shiryen sarrafawa.
Tare da kai da kai da kuma samar da akwatunan rufin, pact kankara, da sauran kayan aikin sarkar ruwa, masu sana'a, da kuma ingantaccen ƙofar sarkar-kofa don bipharmaceutical Products, ciki har da magunguna na gwaji, samfurori nazarin halittu, na'urorin likita sun gama magunguna na magunguna. Dangane da dangantakar hadin kai na dogon lokaci da aka kafa tare da abokan ciniki da zurfin bincike na samar da kayan aikin samar da kayan aikin zazzabi and biological samples, and temperature-controlled storage management of biological samples throughout the innovative drug development lifecycle, covering pharmaceutical research, preclinical research, and clinical research.
Hedkwen a Shanghai, Shanghai Shengshereng yana da manyan cibiyoyin aiki na sarkar ruwan sarkar guda 40 a cikin biranen Beijing da Guangzhou, tare da hanyar sadarwar sabis na yau da kullun. Bugu da kari, kamfanin yana da taimakon kudade a Amurka, Belgium, da kuma kayan aikin abokinta ya rufe kasashe 50 a duniya, da kuma tallafawa yankunan da masana'antar harhada masana'antar masana'antu.
Kamfanin ya samo wanda-daidaitaccen GDP, Tread ɗin GMP, da takardar shaidar tsarin ISO9001. Tare da cikakkiyar fasaha, ingantacciyar hanyar sadarwar sabis, kayan aiki mai mahimmanci, kamfanin ya gina ƙwarewar masana'antar kula da ƙwayoyin cuta 7,000 a cikin masana'antar bipharmaceututicaly, Ciki har da haɗin gwiwa na dogon lokaci tare da mashahurin kamfanoni kamar rukunin Hengru, ƙungiyar Fosun, Chia tai Tianiqing, Junshi Group, Wuxi Apptec, da kuma Alƙulƙanci.
Kafin wannan bayarwa, jimlar raba jari miliyan 340, tare da wannan bayarwa da ba kasa da miliyan 60.0.0.0.0.0.0.0.0.0.30 na wannan bai wuce miliyan 60 ba,% na jimlar babban birnin bayan bayarwa.
Kamar yadda ranar ta sa hannu kan wannan sakamakon sa ido, JIBing kai tsaye a hannun jari miliyan 67.1288% na kamfanin duka hannun kamfanin, sa shi na hannun kamfanin da ya mallaki kamfanin.
JIBing da Xiao ZhongMei hadin gwiwa da kai tsaye iko 42.6249% na hannun jari, wanda ya sanya su ainihin masu ikon bayarwa.
Da yawa daga cikin masu zartarwa a Shengsuneng Logistics sune dangi na Ju Jibing. Mai yiwuwa ne ya nuna cewa matar Jibing, Xiao ZhongMei, tana aiki a matsayin mataimakin darektan sashen; Brotheran uwan Xiao ZhongMei, Xiao Zhonghai, hidima a matsayin mataimakin mulkin tallace-tallace; Kuma surukan Xiao ZhongMei, Pan Xiaxuan, ya zama babban kocin ingancin ingancin sarrafa.
Kamar yadda ranar ta sa hannu kan wannan sakamakon sa ido, kamfanin kamfanin, masu duba, manya manjojin gudanarwa, da mambobin ma'aikatan gudanarwa da ke kai tsaye a kaikaice a kamfanin kamar haka:
Yana da mahimmanci a lura cewa Logists na Shanghai suna alfahari da babban jerin gwanon masu daraja a duka magunguna da masana'antu na dabaru.
Daga cikin su, babban birnin tuddai da almara sune manyan cibiyoyin zuba jari, yayin da aka ba da jari ga jari "Sarakunan hannun jari na Doppon na Jikin Dogistical na Deppon. Junding Xieli yana wakiltar masu hannun jarin jihar.
An fahimci cewa a gaban harkar kuɗin sa a shekara ta 2018, Shengsung Cikin sarkar SF, wanda yake so ya hada kai da Shengsheg Cikin Kasuwanci da Zuba jari. Koyaya, Shengsuneng Cold Sarkar sarkar ya zaɓi don neman wannan damar, ya daina don tsarkakakken tallafin kudade maimakon tabbatar da samun 'yancinsu na gaba.
Shanghai Shengsuneng na shirin bugawa yuan miliyan 900 na wannan lokacin, za a saka hannun jari a hedkwatar R & D cibiyar, da kuma tsarin masu hankali R & D, da kuma babban aikin karin bayani.
A lokacin da aka gabatar da rahoton, Shanghai Shengsuneng ya cimma nasarar shigo da Yuan miliyan 269, da miliyan 637, da kuma 77.3619 miliyan yuan, bi da bi.
Dangane da "Shanghai Shengsuneng Parmaceutical Cold Co., LTD. Kyauta a kan babban rahoton aikace-aikacen da aka tsara (1) na Mataki na 3.1.2 na Shanghai Hukuncin Jerin Kasuwancin Kasuwanci, Wakilai, Ba kasa da Yuan miliyan 150, Amfanin Net a cikin wannan shekarar ba kasa da Yuan miliyan 60, da kuma tarin kuɗi ne ba kasa da Yuan miliyan uku ba, ko kuma mai aiki samun kudin shiga a cikin shekaru uku da suka gabata ba kasa da Yuan biliyan 1 ba. "
1
Masu bincike sun nuna cewa daga shekarar 2022 zuwa 2022, kudaden da kamfanin ya kasance Yuan miliyan 95.23% da 20,95% a cikin 2021 da kuma 2021. A cikin wannan lokacin, fa'idodin biyan kuɗi sun kasance 49.6911 miliyan yuan miliyan 46.4515, kuma 78.6582 miliyan Yuan, tare da ci gaban ci gaban shekara-shekara na 73.98% da -9.01% a cikin 2021 da 2022, bi da bi.
Game da raguwa a cikin ribar net 2022, Shanghai Shengsarg ya bayyana cewa a cikin 2021, akwai kudin shiga na jari na 13.06681 daga yuan miliyan 13.06681 daga yuan yuan miliyan uku daga cikin yuan miliyan pharacetical daidaito daidai. Ya kamata a lura cewa akwai rarrabuwar kawuna tsakanin canje-canje a cikin kudaden shiga da ragar net. A lokacin lokacin rahoton, kudaden shiga sun yawaita da shekaru 20.92%, yayin da ake amfani da ribar raga 9.01% ya ragu da 9.01% shekara-shekara.
Prospectus ya nuna cewa daga 2020 zuwa 2022, babban kayan aikin kasuwancin sun cika 25.24%, 29.08%, da 27.95%, bi da bi. A 2022, babbar hanyar ribar riba ta ci gaba da raguwa, tare da rage shekara-shekara na 1.13%, da raguwar 7.20% idan aka kwatanta da 20.20.
Musamman, babbar ribar ribar don kasuwancin bincike na cigaba da ci gaba da ilimin kimiyyar rayuwa mai kwakwalwa na zamani sune, 3.75%, da kuma 31.93%, bi da bi. Kamfanin ya ce dalilan karawar shekara ta shekaru sun fi karuwar zuba jari da wuraren shakatawa a cikin 'yan shekarun nan, suna kaiwa ga mafi girman matakan farashin kadara; (II) A shekarar 2022, saboda tasirin muhalli na waje, ƙimar ci gaban da aka samu a ƙasa, da abubuwan da suka faru na kayan aiki na gaggawa sun haifar da haɓaka farashin aiki.
A hankali, babban ribar ribar don magunguna na duniya sun kasance 22.85%, 21.32% a cikin 2022% Decline Decline ne galibi saboda: (i) Kokarin kara fadakarwa da fadada fadama a cikin wannan sashi da karfafa farkawa a cikin kasuwar tsakiyar zuwa-ƙarshen. (ii) Babban farashi na farko, an samo shi a cikin 2020, da Yanjia Cak Sarkar, an kafa shi a cikin rabin na biyu na 2021.
A lokacin lokacin rahoton, babban ribar ribar don magunguna na duniya sun kasance 22.85%, da 1122 da kuma yawan raguwa a cikin 2022. Babban dalilai ne: (i) Ayyukan Pharmaceutical Pharmaceutical na kasa da kasa sun kasance har yanzu a cikin saka hannun jari da Kasuwancin Kasuwanci, tare da ƙara kashe kudi don aiki, wuraren shakatawa, da dai sauransu a ciki 2022, kafa Shengsuneng Internationalarin Inji ya kara da hannun jari a wannan sashin; (ii) Saboda tasirin muhalli, dage kudaden sufuri na sufuri ya haifar da ƙara farashin aiki.
A lokacin lokacin rahoton, babban ribar ribar don sarkar calmy Cold Cold Cold Cold Cold Colle Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold Cold. Babbar riba ta riba a cikin 2021 idan aka kwatanta da 2020, galibi saboda 2020 har yanzu yana cikin girman ci gaban kasuwanci a 2022, tattalin arziki na sikelin an gano a hankali. Babbar riba mai dadin daɗaɗa a cikin 2022 idan aka kwatanta da 2021, galibi saboda tasirin muhalli, da kuma haɓaka farashin kuɗi.
A yayin lokacin rahoton, babban ribar ribar don sabbin kayan aiki da kuma kayan aikin kayan aikin sarkar sun kasance 15.02%, da 23.99%, bi da su. Babbar ribar ta ragu a cikin 2021 kuma an sake fasalta a cikin 2022, galibi saboda abokan ciniki na zirga-zirgar hanya sun zama mara nauyi kuma suna rage yawan amfanin gayya. A cikin 2022, tare da rage hadin gwiwar kasuwanci tare da wannan abokin ciniki, babbar hanyar ribar riba.
Idan aka kwatanta da takwarorin siye da ayyukan siye da ayyukan CRO, irin su ba da izinin shiga 2020 ya fi na matsakaicin ci ba, yayin da a shekarar 2021 da 2022, ya yi ƙasa da matsakaici.
Shanghai Shengsuneng ya bayyana cewa idan kasuwar ci gaba ta fara aiki, hakanan farashin tallace-tallace na gaba ya ragu, wannan na iya haifar da raguwa a cikin babban riba.
2
A lokacin da aka gabatar da rahoton, babban kasuwancin Shangshai ya hada da jikoki biyar: bincike mai kwakwalwa da kuma na'urorin da likitanci na yau da kullun, da kuma sabo Kayan aiki da sarkar kayan aikin sarkar. Daga cikin waɗannan, bincike mai ci gaba da ci gaba da haɓaka rayuwar ƙwaƙwalwar ƙwaƙwalwa na yau da kullun, da kashi 41.77810 na Yuan miliyan 219.975, da 69.77% na jimlar kudaden, bi da bi, tare da daidaitawa yana wuce 70%.
Tsarin kasuwanci na biyu mafi girma na biyu, rarraba kayan sanyi na kasuwanci da magunguna da kuma kayan aikin likita, da suka yi wa wani sashi na cigaba da ci gaba da ci gaba da ci gaba da ci gaba kuma Ayyukan Kimiyyar Kimiyya mai Kyau.
Don kamfanonin sanyi na sanyi, ƙarar umarni masu ma'ana ra'ayi ne mai mahimmanci. Shanghai Shengsuneng ya bayyana cewa canje-canje a cikin wannan mai nuna alama suna da tasiri mai hangen nesa game da aiki. A yayin lokacin rahoton, juzu'in kamfanin ya kasance umarni 361,900, kuma umarni 662,200,200,200,200 umarni, bi da bi da bi, da bi da ci gaba. However, the growth rates of 66.13% and 10.14% in 2021 and 2022, respectively, indicate a significant slowdown, which is a worrying signal for Shanghai Shengsheng.
3. Hadarin da ke haifar da lahani, sabunta hanyoyin aiwatarwa, da keta harkar zirga-zirga
Kamar yadda ƙarshen lokacin bayar da rahoton, kamfanin da kuma kudade sun yi amfani da murabba'in murabba'in 6,15.55.5% na kudin da ke aiki ko kuma ofishin ofishi a kasar Sin. Waɗannan kaddarorin suna da maganganu kamar karancin takaddun mallakar mallaki, ana samun su a kan tudu, ko ƙasar da aka keɓe. Idan waɗannan kaddarorin ana ɗauka suna buƙatar rushewar ba bisa ƙa'ida ba kuma ana buƙatar rushewar mallakar kadarori tsakanin masu mallakar ƙasa da sauran ɓangare koiyoyinsu na iya amfani da waɗannan kaddarorin da kullun, suna haifar da haɗarin haɗari.
Aikin kamfanin na Kamfanin Biopharmaceututh na kwastomomi ya ƙunshi matakai masu yawa na buƙatar takaddun rajista, ciki har da lasisin sayar da na'urar na kwastomomi ko masu lasisin kasuwanci, da lasisin kasuwancin sufuri. Wadannan cancantar suna buƙatar sabuntawa ko sabuntawa lokaci-lokaci. Idan kamfanin ya gaza samu ko sabunta waɗannan cancantar, yana iya fuskantar wasu haɗarin doka.
Kamar yadda ƙarshen lokacin bayar da rahoton, kamfanin yana da motocin mallakar kansu 324, tare da laifofin hana zirga-zirga da suka kai ga kaya da kuma hani na hanawa, da 510,600 yuan a kowane rahoto lokacin. Tare da karuwa da adadin motocin da kuma yiwuwar ƙuntatawa na zirga-zirgar ababen hawa, kudaden da ke tattare da keta na iya haɓaka ayyukan kamfanin.
4. Hadarin aiwatar da aikin aikin da aka samu da aka kara tsayayyen tsarin
Kamfanin yana shirin amfani da kudaden da aka ɗaga don "hedkwatarsu R & D cibiyar sarkar sarkar," "Motsa aiki na Motsa aiki," da "karin aiki mai amfani da aiki." Wadannan masu saka hannun jari sun yi ritaya a kusa da babban kasuwancin kamfanin. Kodayake kamfanin ya gudanar da bincike mai cikakken yiwuwa cikakke ga kowane mataki na ayyukan, al'amurran kamar su jinkirta da yanke hukunci da kisan kai na iya tasowa. Bayan kammala aiki, canje-canje a cikin yanayin siyasa, bukatun abokin ciniki, da yanayin kasuwa na iya hana ingantaccen aiwatarwa da kuma aikin kamfanin. Kamar yadda Ranar ta yi nuni da wannan sakamakon, kamfanin ya sanya hannu kan "jingina da hannun jari" na kasar da aka samu ga Sarkar Sarkar Asia Asiya, a gundumar Huacao, Tare da Gundumar Huacao, Tare da Gundumar Huacao, Gundumar Huacao, Tare da Ofishin kwamitin Gudanar da Midhang da Hukumar Junacao. Kamfanin ya sami ra'ayi "Tsari na Revice Aikin MINHANG DANCHANGLOD da" Bayani kan amfani da Ofishin Gudanar da Ginin Shengsareng Post na "Daga Midhanglor Nannongqiong Post, amma har yanzu bai samu ba Hakkokin amfani da ƙasa. Rashin samun mahimmancin amfani da ƙasa mai dacewa na iya hana ingantaccen aiwatar da ayyukan tattara kudaden.
Daga cikin ayyukan tattara kudade, "Hedikwatar R & D Center da R & D cibiyar aikin da aka shirya a hade da yuan biliyan 1.001, tare da kiyasta sabon Zuba jari na Kimanin Yuan miliyan 764 a cikin kayyadaddun kadarorin kamar kayan aiki, gine-gine, da sanyi ajiya. Bayan kammalawa, haɓaka haɓaka a cikin kashedin kuɗi da kuɗin haɓaka na iya zama ba za'a iya kashe kuɗi ta hanyar samun kuɗin shiga nan da nan ba, yana haifar da haɗarin riba ƙi.
Lokaci: Aug-14-2024